摘要
目的 探讨胸水细胞中 p5 3基因突变的检测对鉴别良恶性胸水的价值 .方法 应用 PCR- SSCP方法对 34例肺癌患者和 16例良性肺部疾病患者的胸水细胞中的 p5 3基因突变情况进行了检测 .同时进行了胸水的瘤细胞学检查和部分肺癌组织的 p5 3基因突变检测 ,并将结果进行了比较 .结果 在 47.0 % (16 / 34 )的肺癌患者的胸水细胞中检测到p5 3基因的突变 ,在 37.5 % (6 / 16 )的瘤细胞学检查阴性的肺癌患者的胸水细胞中检测到 p5 3基因的突变 ,在 83.3% (5 /6 )的伴有组织 p5 3基因突变检测阳性的肺癌患者的胸水细胞中检测到 p5 3基因的突变 ,而在全部 16例良性肺部疾病患者的胸水细胞中未检测到 p5 3基因突变 .结论 突变的 p5
AIM To explore the diagnostic value of the method to detect p53 gene mutation in pleural effusion cells of lung cancer patients. METHODS Thirty-four pleural effusion specimens of lung cancer patients and 16 pleural effusion specimens of benign lung disease patients were analyzed to detect p53 gene mutations with PCR-SSCP. 12 lung cancer tissues were studied to find mutant p53 gene with the same method. The common cytological examination was also concurrently performed. RESULTS 47.0% (16/34) of lung cancer patients were detected to show p53 gene mutations in the pleural effusion cells. As to the patients with a negative cytology examination, the positive rate of mutant-p53 gene detection was still 37.5% (6/16). Of the patients with a tissue p53 gene mutation, 83.3% (5/6) were detected to have p53 gene mutation in pleural effusion cells. No p53 gene mutation was found in pleural effusion cells of benign lung disease patients. CONCLUSION Mutant p53 gene may be a valuable tumor marker in the differential diagnosis of malignant pleural effusion caused by lung cancer.
出处
《第四军医大学学报》
2000年第7期869-871,共3页
Journal of the Fourth Military Medical University
